This content is in French.
MoCA boosted, brain relieved!
7 avril 2025
#Parkinson #Cognition #Inflammation #IL6 #Entacapone #MoCA
Parkinson’s disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor symptoms such as tremors, rigidity, and bradykinesia. However, in moderate to advanced stages, non-motor symptoms—particularly cognitive impairments—become increasingly common, affecting memory, attention, executive function, and information processing speed. These cognitive issues significantly impact quality of life, reduce independence, and complicate overall disease management.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor symptoms such as tremors, rigidity, and bradykinesia. However, in moderate to advanced stages, non-motor symptoms—particularly cognitive impairments—become increasingly common, affecting memory, attention, executive function, and information processing speed. These cognitive issues significantly impact quality of life, reduce independence, and complicate overall disease management.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Xu, D., et al. (2025). The efficacy of levodopa/carbidopa/entacapone on cognitive function in moderate to advanced Parkinson's disease and its relationship with peripheral inflammatory cytokines. BMC neurology, 25(1), 116
View the source
